



Company Overview

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer

Aug 31 2026, 9:30 AM EDT

Emmaus Life Sciences Reports Quarterly Financial Results

Aug 14 2026, 4:11 PM EDT

Emmaus Life Sciences Reports Quarterly Financial Results

May 15 2026, 3:51 PM EDT

Stock Overview

Symbol	EMMA
Exchange	OTCQB
Market Cap	4.98m
Last Price	\$0.07
52-Week Range	\$0.00 - \$0.08

09/02/2026 07:59 PM EDT

Management Team

Willis C. Lee, MS

Chief Executive Officer, Director

Charles W. Stark, Pharm.D.

Senior Vice President of Medical Affairs, Clinical, Regulatory

Dale E. Short, JD

Legal Consultant and Corporate Secretary

Hiroko Huynh

Chief Accounting Officer

Emmaus Life Sciences, Inc.

21250 Hawthorne Blvd.
Suite 800
Torrance, CA 90503

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.